Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study

Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study

Abstract Background Canakinumab, an IL-1β inhibitor, has demonstrated long-term efficacy and safety in patients with sJIA, FMF, TRAPS, and MKD/HIDS who experience inadequate disease control with conventional treatments. This non-interventional study aimed to gain insights into canakinumab use and tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Michel Moutschen, Cécile Boulanger, Joke Dehoorne, Rik Joos, Florence Roufosse, Vito Sabato, Jeroen van der Hilst, Eleonore Maury, Hilde Rabijns, Marijn Witterzeel, Carine Wouters
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Rheumatology
Subjects:
Autoinflammatory diseases
Canakinumab
Familial Mediterranean fever (FMF)
Hyperimmunoglobulinemia D syndrome (HIDS)
Mevalonate kinase deficiency (MKD)
Systemic juvenile idiopathic arthritis (sJIA)
Online Access:https://doi.org/10.1186/s41927-025-00515-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41927-025-00515-w

Similar Items